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Statistical Issues in the Design,
Analysis and Interpretation of Animal
Carcinogenicity Studies
by Joseph K. Haseman*
Statistical issues in the design, analysis and interpretation of animal carcinogenicity studies are
discussed. In the area of experimental design, issues that must be considered include randomization of
animals, sample size considerations, dose selection and allocation ofanimals to experimental groups, and
control of potentially confounding factors.
In the analysis oftumor incidence data, survival differences among groups should be taken into account.
It is important to try to distinguish between tumors that contribute to the death of the animal and
"incidental" tumors discovered at autopsy in an animal dying of an unrelated cause. Life table analyses
(appropriate for lethal tumors) and incidental tumor tests (appropriate for nonfatal tumors) are described,
and the utilization ofthese procedures by the National Tbxicology Program is discussed. Despite the fact
that past interpretations ofcarcinogenicity data have tended to focus on pairwise comparisons in general
and high-dose effects in particular, the importance of trend tests should not be overlooked, since these
procedures are more sensitive than pairwise comparisons to the detection of carcinogenic effects.
No rigid statistical "decision rule" should be employed in the interpretation of carcinogenicity data.
Although the statistical significance of an observed tumor increase is perhaps the single most important
piece of evidence used in the evaluation process, a number of biological factors must also be taken into
account. The use ofhistorical control data, thefalse-positive issue andthe interpretation ofnegativetrends
are also discussed.
Introduction
Although the overall evaluation of the results of a
carcinogenicity study in laboratory animals is acomplex
processinvolvingscientificjudgmentwithallitsfrailties,
the process is made less difficult if the experiment has
been properly designed, the data appropriately ana-
lyzed and certain interpretative issues adequately
addressed.
The purpose ofthis paper is to consider in detail each
of these important areas. Statistical design issues
include proper randomization of animals, sample size
considerations, dose selection and animal allocation
issues, and the control of potentially confounding fac-
tors such as littermate and caging effects. Data analy-
ses should employ methodology that takes survival
differences into account and ideally makes use of cause
of death information. Issues of interpretation include
the use of historical controls, awareness of the false-
positive issue and the consideration ofnegative trends.
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Experimental Design
Ifastudy hasbeeninadequatelydesigned, no amount
ofcarefulhistopathologicalevaluationorelegantstatisti-
cal analysis can salvage the experiment. Many design
issues are "nonstatistical" and will not be dealt with
here. Theyinclude speciesand strainofanimalemployed
in the experiment, route of administration, diet, study
duration, caging, intercurrent infectious diseases and
chemical stability. If one or more of these factors is
compromised, the interpretability ofthe study becomes
more difficult. The "statistical" design issues are dis-
cussed below.
Randomization
Animals should be randomly assigned to treated or
controlgroups toinsurethatthere is no selectionbias in
the formulation of these groups. In some instances, a
stratified random sampling scheme may be appropriate:
for example, where animals are first stratified by body
weight and then assigned at random to treated or
control groups. In any case, some formal randomization
scheme should be employed rather than relying onJ. K. HASEMAN
Table 1. Underlying tumor incidence in the high dose group that can be detected with 50%, 70% and 90% power by using
Fisher's exact test with 50 animals per group.
Underlying tumor incidence, %
Spontaneous p < 0.05 test p < 0.01 test
tumor rate, % 50% 70% 90% 50% 70% 90%
0.1 9.5a 11.8 15.8 13.5 16.2 20.5
1.0 11.0 13.8 18.4 15.1 18.2 23.4
3.0 14.0 17.4 22.9 18.9 22.8 29.0
5.0 17.0 20.8 27.0 22.5 26.8 33.3
10.0 24.2 28.8 35.7 30.2 34.9 41.9
20.0 36.8 41.7 49.0 43.2 48.4 56.0
30.0 48.1 53.6 61.1 54.8 59.9 67.0
aThmor incidence; for example, ifthe spontaneous tumor rate is 0.1%, a one-sided Fisher's exact test comparing control and high dose groups
of50 animals each would have a 50% chance ofdetecting an underlying tumor incidence of9.5% in the high dose group. Exact power calculations
for Fisher's exact test were obtained by the method described by Haseman (53).
subjective judgment for assigning animals to treated
and control groups.
Sample Size Considerations
A sufficient number of animals should be included in
the experimental design to insure reasonable power for
detecting carcinogenic effects. The "standard" NCI
design employs 50 animals in each of three groups:
control, low dose and high dose. Table 1 shows the
approximate power ofthis particular design for detect-
ing carcinogenic effects. The actual number of animals
pergroupwilldependuponthespecificstudyobjectives,
but one should always consider the power ofthe design
before the experiment isbegun. Ifinterim kills are tobe
employed, allowance for these extra animals must be
made in the overall experimental design.
Dose Selection and Allocation of Animals
Perhaps no single issue related to the design of
laboratory animal carcinogenicity studies has generated
as much discussion as has dose selection. Since small
numbers ofrodents are servingas surrogates foralarge
human population, and since even the most carefully
documentedhumancarcinogens (e.g., cigarettesmoking)
do not produce tumors in the majority of subjects at
risk, there is general acceptance of the basic principle
that animal testing must be carried out at doses that
exceed a typical human exposure (1-5). Large doses
must be employed to insure reasonable power for
detecting carcinogenic effects. However, there contin-
ues to be debate regarding the actual magnitude of
doses that should be employed in these investigations.
Dose selection for the chronic study is generally
based on the results of a series of subehronic (single-
dose, two-week, and 90-day) toxicity studies. Data from
these experiments that are factored into the dose
selection process include weight gain and survival
information, pharmacokinetic and metabolism data, and
the results ofathorough histopathological examination.
Sontag et al. (6) recommend that the highest dose
employed should be the "maximum tolerated dose"
Table 2. Recommended designs for carcinogenicity studies.a
Group Dose Number of animals
Control 0 50
Low 20-30% MTD 30-40
Middle 50% MTD 60-70
High MTD 50
aFrom Portier and Hoel (13) assuming a total sample size of 200
and a four dose design. MTD = Maximum tolerated dose.
(MTD) which they define as "The highest dose of the
test agent during the chronic study that can be pre-
dicted not to alter the animals' normal longevity from
effectsotherthancarcinogenicity" Thisdefinitionformed
the basis for dose selection in the NCI carcinogenicity
studies and continues to be used by the NTP as well.
Some investigators object to the use of maximum
tolerated doses in carcinogenicity testing. They argue
that these doses are often "too high" and may produce
tumors due to metabolic overloading of the body's
natural detoxification mechanisms or may result in
carcinogenic effects "secondary" to recurrent cytotox-
icity and tissue damage. Several recent papers (7,8)
present a comprehensive discussion of these and other
important issues involved in the selection of doses for
carcinogenicity studies.
Certain disagreements regarding the use of high
doses in carcinogenicity testing seem more related to
the basic definition and estimation of the maximum
tolerated dose rather than to major philosophical
differences. Clearly, doses that produce excessive mor-
tality (apart from that related to chemically induced
carcinogenicity) are undesirable. Onthe otherhand, the
high dose must elicit some signs of toxicity or some
biological effect (2,3,7-11), orthe animals may not have
been sufficiently challenged by the test chemical. The
NTP has recently incorporated an additional lower
dosed group into its study design and this group
provides for a margin ofsafety should the high dose be
overly toxic. NTP also has increased its efforts to obtain
pharmacokinetic and metabolism data for the test
chemical that might be factored into the dose selection
and study evaluation processes.
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Traditionally, equal allocations of animals have been
employed in dosed and controlgroups. However, in some
instances unequal allocation may be preferable. Portier
and Hoel (12,13) investigated various allocations of
animals to derive an "optimal design," where optimality
was defined in terms of the power of the design, the
variability of low-dose risk estimates and the accuracy
ofestimatingthe dose-response curve in the experimen-
tal region. Their final recommended design is given in
Table 2 and involves unequal allocation of animals to
dosed and control groups.
Confounding Factors
If certain factors can be identified that would other-
wise confound the interpretation ofthe study, then the
experimental design should be modified to take these
factors into account. One example is cage location,
which in several studies (14,15) has been shown to be
related toincreasedincidences ofcataracts andretinopa-
thy (because of the proximity of the animals to the
fluorescent light source). This particular problem canbe
dealt with by a systematic rotation ofcages. In addition
to cage location, the housing of more than one animal
per cage may introduce "cage effects" that require
consideration in the subsequent statistical analysis (16).
Littermates may also be a potentially confounding
factor. Littermate information is generally not available
when the animals are received from the supplier and it
is implicitly assumed (reasonably in most cases) that
any "litter effects" have been "balanced out" by the
random assignment of animals to treated or control
groups. Specialized methods of analysis have been
proposed (17,18) if it is desired to employ a formal
litter-matched design.
A more subtle potential source ofbias is a difference
in slide preparation of tissues for histopathological
examination. Ideally, identical procedures should be
employed for dosed and control groups with regard to
the number of slides prepared and the methodology
employed. Occasionally, additional slides may be made
for a particular animal because ofsuspicious "lumps and
bumps" noted at gross necropsy, but the investigator
must be careful that these additional slides do not
introduce bias into the diagnostic process. For example,
if for a particular organ consistently more sections are
examined fordosed animals than forcontrols, one would
expect to find more dosed-group tumors by chance
alone.
A related issue is "blind" pathology, which has tradi-
tionally been the source ofdebate between statisticians
and pathologists. Most statisticians recommend "blind"
pathology (i.e., histologic examination without knowing
the source ofthe tissue) to insure the total objectivity of
the tumor diagnosis. Otherwise, subjective bias could
effect the overall interpretation of the results.
On the other hand, most pathologists feel that the
disadvantages of"blind" pathology outweigh the advan-
tages (19). They assert that control animals must be
examined first to determine the naturally occurring
incidence and severity of neoplastic and nonneoplastic
lesions. They further contend that blind pathology will
require additional time and effort and will introduce the
possibility of coding errors, and that an experienced
pathologist can generally distinguish between tissues
from control and treated animals in any event.
Perhapsareasonablecompromise(currentlyemployed
by the NTP) is to have the original pathologist diagnose
lesions inanonblind fashion. Then, ifapparenttreatment-
related effects are found, these particular tissues can
then be reviewed blindly to determine whether or not
these lesions can be verified under a more rigorous
protocol. If this procedure reveals evidence of bias on
the part of the original pathologist, this raises serious
questions regarding the objectivity of all his pathology
diagnoses, including those which showed no apparent
treatment-related effects.
Methods of Statistical Analysis
Ifa study has been properly designed and executed,
the statistical analysis ofthe dataisobviouslyfacilitated.
The methods of analyses traditionally used by the NCI
in the evaluation oftumor incidence data were Fisher's
exact test for pairwise comparisons and the Cochran-
Armitage test for dose-response trends (20). These
procedures compare directly the proportion of tumor-
bearing animals in dosed and control groups.
In recent years there has been an increased aware-
ness of the need to take intercurrent mortality into
account in the analysis of tumor incidence data.
Consequently, a number of different methods have
been proposed that deal with time-to-death-with-tumor
(21-28).
One simple approach to this problem (used, e.g., in
many ofthe early NCI studies) is to exclude all animals
that died prior to the appearance ofthe first tumor, and
then carry out the analyses described above (Fisher's
exact test; Cochran-Armitage test). In some cases this
approach will be satisfactory, but in other instances
more rigorous methods of analysis may be required.
Perhaps the most comprehensive discussion of this
issue is given by Peto et al. (25). These authors
emphasize the need to determine the "context of
observation" of each tumor, i.e., to determine whether
the tumorcontributed directly orindirectly tothe cause
ofdeath orwhether alternatively the tumor was merely
an incidental finding at autopsy in an animal dying ofan
unrelated cause. The distinction between "fatal" and
"incidental" tumors is important, because in the evalua-
tion of tumor incidence it is essential to distinguish
between a chemical that reduces survival because of
shortened tumorlatency (a real carcinogenic effect) and
one which also reduces survival, but in which tumors
are merely being observed earlier because animals are
dying of some other competing risk (a noncarcinogenic
effect). Hoel and Walburg (21) present an example with
actual experimental animal data to show how a mislead-
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ing result can be obtained ifa "fatal tumors" analysis is
incorrectly applied to incidental tumor data. Mantel et
al. (29) refer to this distinction as whether or not
tumors are "self-evidencing," but the basic principle is
the same.
The primary difficulty with survival-adjusted analy-
ses is the need to determine the context ofobservation
of each tumor on an individual animal basis. Peto et al.
(25) present an example with over4500 tumors in which
94% ofall tumors could be classified as either "definitely
incidental" or "definitely fatal," notwithstanding the
initial reservations of pathologists regarding whether
such determinations could reliably be made. Despite
theseresults, otherpathologists remainskepticalregard-
ingthegeneralaccuracyofcauseofdeathdeterminations.
As part of its new modified pathology protocols, the
National Toxicology Program requests that patholo-
gists attempt to determine contexts of observation for
each tumor observed in NTP studies. It is hoped that
ultimately sufficient data can be generated to evaluate
the feasibility ofutilizing cause-of-death information on
an individual animal basis in the evaluation of NTP
carcinogenicity data.
Most pathologists agree that it is often possible to
judge a priori the likelihood that a particular tumor
type will be fatal or incidental. For example, one simple
rule (admittedly unacceptable for general usage) is that
malignant tumors are generally fatal and benign tumors
are usually incidental. For those tumors determined to
be virtually always "fatal" or"incidental," the context of
observationforindividual animalsbecomeslessimportant.
For fatal tumors, life table methods (23,30) can be
employed to evaluate tumor incidence data. With this
approach, the proportions of tumor-bearing animals in
dosed and control groups are compared at each point in
time when an animal dies with the tumor of interest.
The denominators of these proportions are the total
number of animals at risk in each group. These results
are then combined by Mantel-Haenszel methods (31).
These methods can also be used to pool the "fatal
tumor" analysis with the corresponding comparisons
based on the "incidental tumors" observed at the end of
the experiment to obtain an overall p value. Life table
methods are sensitive both to an increased tumor
incidence and to a shortened latency period.
For nonfatal tumors, the procedure described by Peto
et al. (25), which is ssentially the Hoel-Walburg (21)
method, can be employed. According to this approach,
the proportions of animals found to have tumors in
dosed and control groups are compared at selected time
intervals. The denominators of these proportions are
the number of animals actually autopsied during the
time interval. The individual time interval comparisons
are then combined by Mantel-Haenszel methods to
obtain a single overall result. An example illustrating
the numerical computations for these various methods
of analysis is given in the Appendix.
One disadvantage ofthe incidental tumor test is that
a subjective determination oftime intervals is required
for purposes ofgrouping the data. A further drawback
is that forstudies in which reduced survival inthe dosed
group is severe, the method will have little power
because only those tumors for which there is overlap-
ping survival in dosed and control groups will be
included in the statistical analysis. An alternative
method ofanalysis forincidentaltumors currently being
studied by the NTP is based on logistic regression (28).
In addition to avoiding the disadvantages cited above,
the logistic regression approach allows the investigator
to take into account certain covariables (e.g., cage
location, litter effects) that might otherwise be con-
founding factors in the overall evaluation of the data.
Most statisticians (20,25) seem to believe that one-
tailed tests are generally preferable to two-tailed tests
in the evaluation of tumor incidence data. The reason
forthis preference is that the primary objective ofthese
studiesistoidentifycarcinogens(aone-tailedalternative).
In any case, it should be clearly stated which is being
used when p values are reported.
Despitethefactthatpastinterpretations ofcarcinoge-
nicity data have tended to focus on pairwise compari-
sons in general and high-dose effects in particular (32),
the importance oftrend tests should not be overlooked.
Indeed, Peto et al. (25) state that trend tests combine
'in a reasonably optimal way (and should therefore
usuallysupercede)" theinfornationobtainedfrompairwise
comparisons. Since trend tests utilize information from
all experimental groups simultaneously, they are more
sensitive than pairwise comparisons to the detection of
carcinogeniceffects, whichisanadvantagethatbecomes
moreimportant asthenumberofdosedgroupsincreases.
Ironically, this very sensitivity seems to have limited
the subjective value placed on these tests in the past by
some investigators, namely because of the fear of
making "false positive" decisions (see discussion of this
issue below). Increasing emphasis will likely be given to
trend tests (1) as standard designs begin utilizing
additional dosed groups, (2) as more knowledge is
gained regarding the likelihood offalse positive results,
and (3) as more information is learned about the
patterns of chemically induced dose-response trends.
Interpretation of the Data
Even if a study has been carefully designed and ap-
propriate statistical methodology employed, interpre-
tation of results is a complex process. The following
factors merit special consideration: use of historical
control data, multiple comparisons issues, and interpre-
tation of increased and decreased tumor incidence.
Historical Control Data
Over the past several years, NCI and NTP have ac-
cumulated considerable information on background
tumor rates in mice and rats, particularly the B6C3F1
mouse and the Fischer 344 rat. The concurrent control
group is always the most important control group used
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in the decision making process. However, there are
some instances in which the use of historical control
data can aid an investigator in the evaluation of tumor
incidence data. Two examples are rare tumors and
tumors that show amarginal increase relative to concur-
rent controls (33).
Before historical control data can be used in a
meaningful way, however, there are a number of prob-
lems that must first be addressed. For example, nomen-
clature differences must be resolved. Thatis, nomencla-
ture conventions and diagnostic criteria should be
identicalforallstudiesinthehistoricalcontroldatabase.
Then, a decision has to be made regarding which
studies should be included in the database. Next, the
sources of variability in historical control tumor rates
must be identified, and ifpossible, controlled. There are
certain tumors that show considerable (extrabinomial)
study-to-study variability. What factors are responsible
for this variability?
NTP has identified two major sources ofvariability in
historical control tumor rates: calendar year and
laboratory. That is, tumor rates do seem to change over
time, and limiting the data base to more recent studies
helps control this source of variability. Secondly,
laboratory-to-laboratory variability seems to be quite
large for certain tumors. Thus, NTP currently gives
primary emphasis to laboratory-specific tumor rates.
Finally, if historical control data are to be used in a
formal testing framework, statistical procedures that
adjust forextrabinomial variability should be employed.
Three procedures that have been proposed for taking
extrabinomial variability into account (34-36) are cur-
rently being studied by the NTP A recent publication
(37) considers the historical control issue in
detail.
Multiple Comparison Considerations
Another important interpretative issue in carcinoge-
nicity testing is how to take multiple comparisons into
account. Since each NTP study consists offour separate
experiments, with approximately 30 tissues examined
per animal and a battery of statistical tests employed,
the potential exists for finding false positives, i.e.,
statistically "significant" differences that are merelydue
to chance variation alone. Whenconsideringthis issue it
should be kept in mind that the false positive "problem"
is limited primarily to common tumors, since for rare
tumors it is virtually impossible for a sufficient number
to occur in any one study by chance alone to lead to a
statistically significant result.
One possible strategy to deal with this problem
(employed, e.g., in the early NCI bioassays) is to use a
Bonferonni-type multiple comparisons adjustment. A
discussion ofBonferonni adjustments has been given by
Mantel (16).
Because interpretation of carcinogenicity data is a
complex process, other investigators believe that it is
not necessary to employ any formal rigid multiple-
comparisons adjustment. As noted by Peto et al. (25),
"P-values are objective facts, but unless a p-value is
very extreme, the proper use of it in the light of other
information to decide whether or not the test agent
really is carcinogenic involves subjective judgement!'
Thus, no rigid "decision rule" should be employed in
the interpretation ofcarcinogenicity data. Although the
statistical significance ofan observed tumor increase is
perhaps the single most important piece of evidence
used in the evaluation process, a number of other
factors must be taken into account as well: (1) whether
the effect was dose-related, (2) whether the effect was
supported by related nonneoplastic changes and/or by
similarevidence inothersex-speciesgroups, (3)whether
the effect occurred in a target organ, (4) relative
survival of dosed and control animals, (5) the historical
rate of the particular tumor, and (6) the biological
"meaningfulness" of the effect.
Are false positives a major problem in NCI/NTP
carcinogenicity studies? Certain investigations of this
issue (which assumed that any p < 0.05 effect was
automatically regarded as biologically meaningful) esti-
matedthese rates to be quite high: 20 to 50% for asingle
sex-species group (38). Other investigators questioned
the validity of this particular decision rule and empha-
sized (as discussed above) that the interpretation of
carcinogenicity results incorporates biological knowl-
edge and corroborative evidence such as the presence of
a dose-response relationship or experimentally consis-
tent results in different species or sexes (39). These
investigators and other researchers (20,40) concluded
that the overall false-positive rate generally does not
greatly exceed the nominal level.
In a recent examination of25 NTP feeding studies, a
simple statistical rule was derived which appears to
mimic closely the scientific judgment process used in
these experiments. This "rule" was as follows: regard
as carcinogenic any chemical that produces a high-dose
increase inacommontumorthatisstatistically significant
at the 0.01 level or ahigh-dose increase in an uncommon
tumorthat is statistically significant at the 0.05 level. It
should be re-emphasized that no rigid decision proce-
dure was (or should be) used in these studies. However,
theoverallfalse-positive rate associated withthispartic-
ulardecision rule (which appears to closely approximate
the overall evaluation process) was estimated and found
to be no more than 7 to 8% (41). Thus, false positives do
not appear to be a major problem in NCI/NTP studies.
Increased and Decreased Tumor
Incidences
Onenoteworthycharacteristic ofNCI/NTPcarcinoge-
nicity studies is the tendency of these experiments to
show significantly decreased as well as increased tumor
incidences. In fact, an examination of 25 recent NTP
feeding studies revealed that the frequencies ofstatisti-
cally significant (p < 0.01) increases and decreases in
tumor incidence in these studies were approximately
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the same (42). Some investigators have responded to
these types offindings by taking the position that such
studies are uninterpretable, should be abandoned
altogether, and a"drastically different design" employed
(43).
Other authors feel that a more prudent and scientific
course of action is to investigate the patterns oftumor
increases and decreases and attempttoidentifypossible
causal factors, as well as to better characterize the
biologic process or processes responsible for these
opposingresponses(44). Survivaldifferencescanaccount
for many ofthe decreased tumor incidences observed in
dosed groups, since ifthe chemical's toxic effect results
in early mortality, these animals may not have survived
sufficiently long to be considered at risk for developing
tumors.
Another explanatory factor is decreased weight gain.
Frequently, the chemical under test reduces body
weight gain, and decreased incidences of certain endo-
crine and reproductive system tumors (notably mam-
mary gland fibroadenoma in female F344 rats) are
clearly related to decreased weight gain in the dosed
groups (42). This result agrees with similar observa-
tions made in earlier studies (45-49).
Haseman (42)alsofound aninversecorrelationbetween
the incidences of liver tumors and leukemia in F344
rats. A similar negative association between the inci-
dences of lymphomas and liver tumors in CF-1 mice
exposed to DDT was reported by Breslow et al. (50).
This result was confirmed in a later study (51) that
involved extensive serial sacrifice and thus overcame
doubts about whether the original finding may have
been an artifact of the rapid lethality of lymphomas.
The point is that while one should not ignore negative
trends in tumor incidence, a closer examination of the
data may in many cases reveal possible associations that
may serve as explanatory factors. Also, one should not
rule out the possibility that in some instances certain
chemicals may in fact exhibit "true" anti-carcinogenic
effects.
Appendix
In this section we give a detailed comparison of the
three methods of analysis used most often in the
analysis of tumor incidence data: the fatal tumors
(life-table) analysis, Peto's incidental tumors analysis
and the Cochran-Armitage linear trend test.
The discussion that follows deals with only the trend
tests but similar comments apply for the pairwise
comparisons. All three test procedures follow the same
basicapproach: (1)breakdownthedatabytimeinterval;
(2) calculate expected number of tumors in each time
interval; (3) calculatethecorrespondingvarianceterm V;
(4) combine the data over all time intervals, compare
observed and expected tumor incidence, and calculate
the final test statistic.
The primary differences between the procedures are
as follows.
The Cochran-Armitage test in essence uses a single
time interval (the entire study period) and hence does
not adjust for intercurrent mortality. In situations in
which there is a marked treatment effect on survival,
this can be a serious shortcoming of this approach.
Thefataltumorsanalysis assumesthat alltumors ofa
given type in animals dying prior to terminal sacrifice
(TS) are"fatal," (i.e., eitherdirectly orindirectlycaused
the death ofthe animal). The incidental tumors analysis
assumes that all such tumors are 'incidental," (i.e.,
were merely observed at autopsy in animals dying ofan
unknown orunrelated cause). Atpresent NTPprotocols
do not require specification of the cause of death for
each individual animal, soitis not possible to determine
preciselywhichtumorsarefatalandwhichareincidental.
The Cochran-Armitagetestdoes notrequire anassump-
tion regarding tumor "lethality"
For a particular time interval the fatal tumors analy-
sis is based on all animals alive at the beginning ofthe
interval. In contrast, the incidental tumors analysis is
based only on the animals that die and are autopsied
during the interval.
For the fatal tumors analysis, each week at which a
tumor is observed is regarded as a separate "time
intervalf For the incidental tumors analysis, there is a
certainflexibilitywithregard tochoiceoftimeintervals,
and NTP generally uses (for a 2-year study) five time
intervals (expressed asweeks): 0-52, 53-78, 79-92, 93-TS
and TS.
An example is now presented which illustrates the
three methods. The data are taken from the NTP
11-Aminoundecanoic Acid Technical Report (52), and
the lesions are malignant lymphoma in male mice.
Let 0 denote the number ofobserved tumors; E, the
numberofexpected tumors;Nthe numberofanimals at
risk; and D, dose levels [without loss of generality (for
equally spaced doses) taken as 0,1,2]. E denotes
summation, and R are the 10 for a given time interval
and M are IN for a given time interval.
Then, for each time interval, for the three dose
groups i, we have
Ei = NiRIM i = 1,2,3
and
v - (M - R)R[M ND2 - (IND)2]
M2 (M- 1)
[The Cochran-Armitage test uses M3 rather than
M2(M - 1) in the denominator of V].
The individual values of0, E and Vare then summed
over all time periods, and the final test statistic is based
on the total and can be calculated as
Z = ID(O - E)/(P0-5
The p-value that corresponds to this test statistic
can be found from tables of the Standard Normal
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Table A-1.
Controls Low dose High dose
Time interval, weeks 0 E N 0 E N 0 E N V
0-109 2 5 50 9 5 50 4 5 50 9
Table A-2.
Controls Low dose High-dose
Time interval, weeks 0 E N 0 E N 0 E N V
73 0 0.405 47 0 0.371 43 1 0.224 26 0.5965
85 1 0.415 44 0 0.387 41 0 0.198 21 0.5661
88 0 0.404 42 0 0.394 41 1 0.202 21 0.5650
93 0 0.414 41 1 0.384 38 0 0.202 20 0.5712
100 0 0.427 41 1 0.375 36 0 0.198 19 0.5725
106 0 0.407 37 0 0.385 35 1 0.209 19 0.5763
107 0 0.411 37 1 0.389 35 0 0.200 18 0.5665
109 1 3.326 37 6 3.056 34 1 1.618 18 4.2150
Ibtal 2 6.209 9 5.740 4 3.051 8.2291
Table A-3.
Controls Low dose High dose
Time interval, weeks 0 E N 0 E N 0 E N V
0-52 0 0 2 0 0 3 0 0 22 0.0000
53-78 0 0.154 2 0 0.462 6 1 0.385 5 0.4852
79-92 1 0.909 5 0 0.545 3 1 0.545 3 1.2496
93-108 0 1.600 4 3 1.600 4 1 0.800 2 1.4933
109 1 3.326 37 6 3.056 34 1 1.618 18 4.2150
Ibtal 2 5.989 9 5.663 4 3.348 7.4431
Distribution. For the Cochran-Armitage linear trend
test, we have, for the values shown in Table A-1,
Z = [(9 - 5) + 2(4 - 5)]/(9)05 = 0.67, p = 0.252
The Cochran-Armitage test currently employed by
the NTP uses a continuity correction, i.e.,
Z = [1(9 - 5) + 2(4 - 5)1 - 0.5]/(9)°5 = 0.50,
p = 0.309
For the fatal tumor (life table) analysis we have, for
the data of Table A-2,
Z = [(9 - 5.740) + 2(4 - 3.051)]/(8.2291)°5 = 1.798,
p = 0.036
or, if a continuity correction is employed,
Z = [1(9 - 5.74) + 2(4 -3.051)1-0.5]/(8.2291)0o5 = 1.624,
p = 0.052
For the Peto incidental tumor analysis we have, for
the data of Table A-3,
Z = [(9 - 5.663) + 2(4 - 3.348)]/(7.4431)0-5 = 1.701,
p = 0.044
or, if a continuity correction is employed,
Z = [1(9 -5.663) + 2(4 -3.348)l-0.5]/(7.4431)° 5 = 1.518,
p = 0.065
For these data, adjusting for intercurrent mortality
revealed some evidence of a dose-related trend that
wouldhavebeenmissedhadtheusual Cochran-Armitage
test been carried out. This latter test does not take into
accountthefact that at the high dose44% ofthe animals
died during the first year (compared with 4% of the
controls) and the first malignant lymphoma was not
observed until week 73.
I would like to thank Drs. Michael Hogan andJames Hufffor their
helpful suggestions and Ms. Kay Moore for typing this manuscript.
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